| Bioactivity | Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD)[1]. |
| In Vivo | Mavodelpar (10 mg/kg；腹腔注射，10 mg/kg，每日 1 次，6-17 周龄) 可有效抑制肾小球损伤和肾纤维化，并降低纤维化相关蛋白的水平[1]。 Animal Model: |
| Name | Mavodelpar |
| CAS | 1604815-32-8 |
| Formula | C31H29FNNaO5 |
| Molar Mass | 537.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Omachi K, et al. PPARδ agonism ameliorates renal fibrosis in an Alport syndrome mouse model. Kidney360. 2022 Nov 29. |
Mavodelpar
CAS: 1604815-32-8 F: C31H29FNNaO5 W: 537.55
Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpa
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.